JoAnn D Kuruc
Overview
Explore the profile of JoAnn D Kuruc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKellar M, Keys J, Filiatreau L, McGee K, Kuruc J, Ferrari G, et al.
J Antimicrob Chemother
. 2024 Nov;
80(1):169-174.
PMID: 39504491
Background: Antiretroviral therapy (ART) is recommended for all individuals with HIV infection, including those with acute HIV-1 infection (AHI). While recommendations are similar to those for chronic infection, efficacy data...
2.
Lee S, Sondgeroth A, Xu Y, Warren J, Zhou S, Gilleece M, et al.
Open Forum Infect Dis
. 2024 May;
11(5):ofae212.
PMID: 38756763
Background: Persistence of HIV-1 in reservoirs necessitates life-long antiretroviral therapy (ART). There are conflicting data using genetic analysis on whether persistence includes an actively replicating reservoir with strong evidence arguing...
3.
Gay C, Hanley P, Falcinelli S, Kuruc J, Pedersen S, Kirchherr J, et al.
J Infect Dis
. 2024 Feb;
229(3):743-752.
PMID: 38349333
Background: The histone deacetylase inhibitor vorinostat (VOR) can reverse human immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells in vitro. HIV-specific T...
4.
Clutton G, Weideman A, Mischell M, Kallon S, Conrad S, Shaw F, et al.
Clin Exp Immunol
. 2023 Nov;
215(3):279-290.
PMID: 37950348
CD8 T cells recognize infected and cancerous cells via their T-cell receptor (TCR), which binds peptide-MHC complexes on the target cell. The affinity of the interaction between the TCR and...
5.
Falcinelli S, Peterson J, Turner A, Irlbeck D, Read J, Raines S, et al.
J Clin Invest
. 2022 Apr;
132(8).
PMID: 35426377
Latency reversal strategies for HIV cure using inhibitor of apoptosis protein (IAP) antagonists (IAPi) induce unprecedented levels of latent reservoir expression without immunotoxicity during suppressive antiretroviral therapy (ART). However, full...
6.
Gay C, James K, Tuyishime M, Falcinelli S, Joseph S, Moeser M, et al.
J Infect Dis
. 2021 Sep;
225(5):856-861.
PMID: 34562096
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting...
7.
Gaebler C, Falcinelli S, Stoffel E, Read J, Murtagh R, Oliveira T, et al.
J Virol
. 2020 Dec;
95(6).
PMID: 33361426
The HIV proviral reservoir is the major barrier to cure. The predominantly replication-defective proviral landscape makes the measurement of virus that is likely to cause rebound upon antiretroviral therapy (ART)-cessation...
8.
Falcinelli S, Kilpatrick K, Read J, Murtagh R, Allard B, Ghofrani S, et al.
J Infect Dis
. 2020 Nov;
224(1):92-100.
PMID: 33216132
Background: The replication-competent human immunodeficiency virus (HIV) reservoir is the major barrier to cure. The quantitative viral outgrowth assay (QVOA), the gold-standard method to quantify replication-competent HIV, is resource intensive,...
9.
Warren J, Zhou S, Xu Y, Moeser M, MacMillan D, Council O, et al.
Elife
. 2020 Oct;
9.
PMID: 33021198
HIV-1-specific CD8+ T cells are an important component of HIV-1 curative strategies. Viral variants in the HIV-1 reservoir may limit the capacity of T cells to detect and clear virus-infected...
10.
Stuelke E, James K, Kirchherr J, Allard B, Baker C, Kuruc J, et al.
Front Immunol
. 2020 Aug;
11:1971.
PMID: 32849659
Quantifying the inducible HIV reservoir provides an estimate of the frequency of quiescent HIV-infected cells in humans as well as in animal models, and can help ascertain the efficacy of...